Assertio Appoints New Directors Amid Nasdaq Halt and Delisting

Assertio, a pharmaceutical company, has recently announced the appointment of two new directors to its board. This move comes at a critical time for the company, which is currently facing a trading halt and the possibility of being delisted from the Nasdaq stock exchange.

The appointments are seen as a strategic step to strengthen the company's leadership and navigate the challenges it is facing. The newly appointed directors bring a wealth of experience and expertise to the table, which is expected to help Assertio regain its footing and comply with Nasdaq's listing requirements.